Cannabis-based drug under development for Tourette
Therapix Biosciences’ first-in-class, proprietary investigational drug candidate is to be developed into a softgel product in the US.
Therapix Biosciences’ first-in-class, proprietary investigational drug candidate is to be developed into a softgel product in the US.
Therapix Biosciences demonstrates reversal of age-related cognitive impairment in pre-clinical study.
CURE Pharmaceutical and Israel’s Therapix Biosciences sign MoU with Israel’s Assuta Medical Centers to develop first-in-class therapeutic products.
Israeli researchers restore the memory performance of lab mice to a juvenile stage. Clinical trials on humans are next.
Israeli research and development in traditional areas like agriculture technologies are crystallizing into new market areas for cannabis.
ISA Scientific plans a Phase 2 trial to test the effects of a cannabinoid compound against diabetes as well as inflammatory and heart diseases.
Cannabics Pharmaceuticals says its innovative technology puts standard doses of the medicinal cannabis compounds into a sustained-release capsule.